FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322775500> ?p ?o ?g. }

• W4322775500 endingPage "64" @default.
• W4322775500 startingPage "P4" @default.
• W4322775500 abstract "Abstract Background: Breast cancer is the most common type of neoplasm in women. According to statistics from Globocan 2020, the incidence of breast cancer in Ecuador, as well as worldwide is 47.8 per 100,000 people/year, with a mortality rate of 13.6 per 100,000 people/year. Our health system provides coverage to approximately 60% of the population by the Ministry of Public Health (MSP), 30% by The Ecuadorian social security Institute (IESS), 5% by other entities (ISSFA, ISSPOL, MUNICIPIOS), and &lt; 3% of the population have private medical coverage. Medical care attentions for breast cancer, covered by the MSP was 7,134 consults in 2013, with an increase to 8,767 in 2018. SOLCA Guayaquil, as a national reference Center, provides 24.425 oncologic consults per year, with 38% corresponding to breast cancer. The presentation of breast cancer, at diagnosis, corresponds approximately to 63% in localized stage, 29% as locally advanced, 6% as metastatic disease, with a 5-year overall survival of 99%, 85% and 29% respectively. The proportion of clinical stage IV breast cancer diagnoses varies from 5-10%, with an average of 6% in urban areas, reaching up to 50% in rural areas, so metastatic breast cancer is a public health challenge, especially for countries with emerging economies like ours. Methods: An observational, retrospective, descriptive, single-center study was carried out. All patients with metastatic breast cancer who had been treated at the National Oncology Institute SOLCA Guayaquil, in the period from 2016 to 2020 were included in the analysis. The clinical and pathological characteristics were recorded and their impact on overall survival was calculated by the Kaplan-Meier method and compared by the long-rank test, multivariable adjusted hazard ratios (HR) were estimated by Cox regression models. Results: 3700 patients were identified between January 2016-December 2020. A total of 2587 patients were excluded. Of a total of 1113 remaining patients, 84 debuted as metastatic disease. No male patients where reported with metastatic breast cancer in the past 5 years. Median age at diagnosis was 53,31 years (28-88 years). The most frequent metastatic sites, were: bone 63.86% (N:53), lungs 50.6% (N:42), liver 30,12% (N:25), soft tissue 22.89% (N:19), CNS 16.87% (N:14); A multivariable analysis was performed, all metastatic sites have a higher risk of mortality vs not having any metastasis, but the only significant one is CNS metastases RR 1.31 (1.08-1.61), p&lt; 0.005. A total of 28 patients (33.73%) had 2 metastatic sites at presentation; 21 patients (25.30%) had 3 o more metastatic sites at presentation with a RR 1,22 (0.95-1,57) p:0,011, with overall survival -OS- (36 months vs 15 months) (long Rank 0,001). ECOG 1 was reported in 59 patients (71.08%), ECOG 2 in 18 (21.69%) and ECOG 3 in 5 (6,02%). A multivariable analysis was perform with ECOG 2-3, RR 1.03 (0,43-2-44), p:0,94. Principal reported comorbidities where: hypertension in 28 patients (33,73%), dyslipidemia in 16 (19,28%), obesity 14 (16,87%), Diabetes 8 (9,64%). By grouping 2 or more comorbidities, the RR 1,04 (0,83-1.30), p:0,71. Surgery was classified as done or not, where 33 patients (39,77%) underwent rescue mastectomy. Multivariable analysis shows Not Surgery with a RR 1,88 (1.07-3,3) p:0.02. Median OS was estimated for surgery 44,48 months +/-4,7SD; Not surgery 20,72 months +/-2,8 SD. Conclusions: In our population, metastatic breast cancer occurs in 7.6% (84 patients out of 1113 total), similar to that reported worldwide. Being a neoplasm with multiple immunophenotypes, and therefore, different treatment options, OS depends on multiple clinicopathological variables. This study showed that CNS metastases have a negative impact on OS, it is an independent variable for RR of mortality. ECOG and comorbidities did not show an impact on OS. Ultimately, mastectomy was offered to patients with good clinical response to systemic chemotherapy, and shows positive impact in OS. Citation Format: Elina A. Rodriguez-Melendez, Emiliano Pulla-Cadmilema, Lissette P. Velez Avila, Maria del Mar Sanchez Salazar, Patricia Tamayo Aguilar, Lissette Yagual Bohorquez, Jimmy Martin-Delgado, Glenda Ramos Martinez, Katherine Garcia Matamoros, Mayra Santacruz Maridueña, Ruth Engracia Vivanco, Roberto Escala Cornejo, Felipe Campoverde Merchan, Isabel Delgado Guerrero, Veronica Torres Floril, Diego Garcia Gamboa, Luis Pendola Gomez, Elizabeth Gamarra Cabezas, Juan Carlos Garces Santos, Evelyn Valencia-Espinoza. Impact of baseline ECOG, comorbidities, and surgery treatment election on overall survival [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-07-64." @default.
• W4322775500 created "2023-03-03" @default.
• W4322775500 creator A5000539110 @default.
• W4322775500 creator A5008500907 @default.
• W4322775500 creator A5008920378 @default.
• W4322775500 creator A5009878097 @default.
• W4322775500 creator A5010327438 @default.
• W4322775500 creator A5023490676 @default.
• W4322775500 creator A5028980608 @default.
• W4322775500 creator A5037926966 @default.
• W4322775500 creator A5038864907 @default.
• W4322775500 creator A5042406370 @default.
• W4322775500 creator A5043919988 @default.
• W4322775500 creator A5046664234 @default.
• W4322775500 creator A5047240937 @default.
• W4322775500 creator A5048875993 @default.
• W4322775500 creator A5055962030 @default.
• W4322775500 creator A5057964972 @default.
• W4322775500 creator A5059031846 @default.
• W4322775500 creator A5060394372 @default.
• W4322775500 creator A5083286852 @default.
• W4322775500 creator A5084783975 @default.
• W4322775500 date "2023-03-01" @default.
• W4322775500 modified "2023-10-18" @default.
• W4322775500 title "Abstract P4-07-64: Impact of baseline ECOG, comorbidities, and surgery treatment election on overall survival" @default.
• W4322775500 doi "https://doi.org/10.1158/1538-7445.sabcs22-p4-07-64" @default.
• W4322775500 hasPublicationYear "2023" @default.
• W4322775500 type Work @default.
• W4322775500 citedByCount "0" @default.
• W4322775500 crossrefType "journal-article" @default.
• W4322775500 hasAuthorship W4322775500A5000539110 @default.
• W4322775500 hasAuthorship W4322775500A5008500907 @default.
• W4322775500 hasAuthorship W4322775500A5008920378 @default.
• W4322775500 hasAuthorship W4322775500A5009878097 @default.
• W4322775500 hasAuthorship W4322775500A5010327438 @default.
• W4322775500 hasAuthorship W4322775500A5023490676 @default.
• W4322775500 hasAuthorship W4322775500A5028980608 @default.
• W4322775500 hasAuthorship W4322775500A5037926966 @default.
• W4322775500 hasAuthorship W4322775500A5038864907 @default.
• W4322775500 hasAuthorship W4322775500A5042406370 @default.
• W4322775500 hasAuthorship W4322775500A5043919988 @default.
• W4322775500 hasAuthorship W4322775500A5046664234 @default.
• W4322775500 hasAuthorship W4322775500A5047240937 @default.
• W4322775500 hasAuthorship W4322775500A5048875993 @default.
• W4322775500 hasAuthorship W4322775500A5055962030 @default.
• W4322775500 hasAuthorship W4322775500A5057964972 @default.
• W4322775500 hasAuthorship W4322775500A5059031846 @default.
• W4322775500 hasAuthorship W4322775500A5060394372 @default.
• W4322775500 hasAuthorship W4322775500A5083286852 @default.
• W4322775500 hasAuthorship W4322775500A5084783975 @default.
• W4322775500 hasConcept C120665830 @default.
• W4322775500 hasConcept C121332964 @default.
• W4322775500 hasConcept C121608353 @default.
• W4322775500 hasConcept C126322002 @default.
• W4322775500 hasConcept C146357865 @default.
• W4322775500 hasConcept C151730666 @default.
• W4322775500 hasConcept C23131810 @default.
• W4322775500 hasConcept C2778527826 @default.
• W4322775500 hasConcept C2908647359 @default.
• W4322775500 hasConcept C530470458 @default.
• W4322775500 hasConcept C61511704 @default.
• W4322775500 hasConcept C71924100 @default.
• W4322775500 hasConcept C86803240 @default.
• W4322775500 hasConcept C99454951 @default.
• W4322775500 hasConceptScore W4322775500C120665830 @default.
• W4322775500 hasConceptScore W4322775500C121332964 @default.
• W4322775500 hasConceptScore W4322775500C121608353 @default.
• W4322775500 hasConceptScore W4322775500C126322002 @default.
• W4322775500 hasConceptScore W4322775500C146357865 @default.
• W4322775500 hasConceptScore W4322775500C151730666 @default.
• W4322775500 hasConceptScore W4322775500C23131810 @default.
• W4322775500 hasConceptScore W4322775500C2778527826 @default.
• W4322775500 hasConceptScore W4322775500C2908647359 @default.
• W4322775500 hasConceptScore W4322775500C530470458 @default.
• W4322775500 hasConceptScore W4322775500C61511704 @default.
• W4322775500 hasConceptScore W4322775500C71924100 @default.
• W4322775500 hasConceptScore W4322775500C86803240 @default.
• W4322775500 hasConceptScore W4322775500C99454951 @default.
• W4322775500 hasIssue "5_Supplement" @default.
• W4322775500 hasLocation W43227755001 @default.
• W4322775500 hasOpenAccess W4322775500 @default.
• W4322775500 hasPrimaryLocation W43227755001 @default.
• W4322775500 hasRelatedWork W112778213 @default.
• W4322775500 hasRelatedWork W2038638536 @default.
• W4322775500 hasRelatedWork W2108089761 @default.
• W4322775500 hasRelatedWork W2586280594 @default.
• W4322775500 hasRelatedWork W2756083593 @default.
• W4322775500 hasRelatedWork W3000073660 @default.
• W4322775500 hasRelatedWork W3043892729 @default.
• W4322775500 hasRelatedWork W3131130130 @default.
• W4322775500 hasRelatedWork W4297538545 @default.
• W4322775500 hasRelatedWork W4312139631 @default.
• W4322775500 hasVolume "83" @default.
• W4322775500 isParatext "false" @default.
• W4322775500 isRetracted "false" @default.
• W4322775500 workType "article" @default.